A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : VEGFR

Search Conditions:
Search Keyword : VEGFR
Search Method : Exact match.
Research Area:

Abbreviation: VEGFR
Appearance Frequency: 1607 time(s)
Long forms: 18

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
vascular endothelial growth factor receptor
(990 times)
(374 times)
EGFR (141 times)
PDGFR (124 times)
VEGF (116 times)
1998 Expression of endothelial nitric oxide synthase in human and rabbit gastrointestinal smooth muscle cells.
VEGF receptor
(543 times)
(187 times)
VEGF (414 times)
RCC (26 times)
HUVECs (20 times)
1996 Molecular cloning of Quek 1 and 2, two quail vascular endothelial growth factor (VEGF) receptor-like molecules.
vascular endothelial growth factor
(25 times)
(8 times)
EGFR (8 times)
PDGFR (4 times)
MAPK (3 times)
2004 Expression of vascular endothelial growth factor receptor-2 or Tie-2 on peripheral blood cells defines functionally competent cell populations capable of reendothelialization.
anti-VEGF receptor
(16 times)
(8 times)
VEGF (13 times)
EGFR (2 times)
mTOR (2 times)
2003 VEGF regulates the proliferation of acid-exposed alveolar lining epithelial cells.
VEGF and its receptor
(14 times)
(4 times)
VEGF (10 times)
ELISA (2 times)
OS (2 times)
2000 Kidney vasculogenesis and angiogenesis: role of vascular endothelial growth factor.
VEGF-VEGF receptor
(5 times)
(2 times)
VEGF (2 times)
EOC (1 time)
HUVECs (1 time)
2003 CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
anti-VEGF/VEGF receptor
(3 times)
Pharmaceutical Preparations
(1 time)
VEGF (3 times)
eNOS (1 time)
GMP (1 time)
2017 Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels.
anti-vascular endothelial growth factor
(1 time)
(1 time)
IL-2 (1 time)
RCC (1 time)
TKIs (1 time)
2014 Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art.
vascular EGFR inhibitors
(1 time)
(1 time)
BTC (1 time)
EGFR (1 time)
GP (1 time)
2016 Chemotherapy for advanced biliary tract carcinoma: A meta-analysis of randomized controlled trials.
10  VEGF and its receptor family
(1 time)
Cell Transformation, Neoplastic
(1 time)
MUC1 (2 times)
2021 Crosstalk between MUC1 and VEGF in angiogenesis and metastasis: a review highlighting roles of the MUC1 with an emphasis on metastatic and angiogenic signaling.
11  VEGF binding to its receptor
(1 time)
(1 time)
TK (1 time)
VEGF (1 time)
2011 Recent advances in antiangiogenic agents with VEGFR as target.
12  VEGF genes and their receptors
(1 time)
(1 time)
AMD (1 time)
ANOVAs (1 time)
FIGF (1 time)
2013 Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.
13  VEGF ligand to the membrane-bound receptors
(1 time)
VEGF (1 time)
2013 The impact of high density receptor clusters on VEGF signaling.
14  VEGF or the kinase activity of its receptor
(1 time)
(1 time)
--- 2009 [Angiogenesis: a new therapeutic target of thoracic and laryngopharyngeal carcinoma].
15  VEGF receptor tyrosine kinases
(1 time)
Antineoplastic Agents
(1 time)
HGF (1 time)
2013 A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.
16  VEGF tyrosine kinase receptor
(1 time)
(1 time)
TGF-beta1 (1 time)
VEGF (1 time)
1996 Transforming growth factor beta 1 down-regulates vascular endothelial growth factor receptor 2/flk-1 expression in vascular endothelial cells.
17  VEGF-D, and their receptor
(1 time)
(1 time)
VEGF (1 time)
2008 Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
18  vs. adjacent liver were significantly higher
(1 time)
(1 time)
HCC (1 time)
ICC (1 time)
2018 Microvessel density and angiogenesis in primary hepatic malignancies: Differential expression of CD31 and VEGFR-2 in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.